150 related articles for article (PubMed ID: 26160181)
1. Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.
Kurokawa M; Watanabe Nemoto M; Harada R; Kobayashi H; Horikoshi T; Kanazawa A; Togasaki G; Abe Y; Chazono H; Hanazawa T; Okamoto Y; Uno T
J Radiat Res; 2015 Sep; 56(5):849-55. PubMed ID: 26160181
[TBL] [Abstract][Full Text] [Related]
2. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
3. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
4. Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Ota Y; Kodaira T; Fujii H; Shimokawa M; Yokota T; Nakashima T; Monden N; Homma A; Ueda S; Akimoto T
Int J Clin Oncol; 2022 Nov; 27(11):1675-1683. PubMed ID: 36001247
[TBL] [Abstract][Full Text] [Related]
5. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation.
Yamazaki T; Enokida T; Wakasugi T; Zenda S; Motegi A; Arahira S; Akimoto T; Tahara M
Jpn J Clin Oncol; 2016 Sep; 46(9):825-31. PubMed ID: 27317736
[TBL] [Abstract][Full Text] [Related]
6. [The Combination of Molecular Targeted Agents with Radiotherapy in Head and Neck Cancer].
Furuta M; Yokota T
Gan To Kagaku Ryoho; 2018 Mar; 45(3):419-423. PubMed ID: 29650896
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O
Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.
Addeo R; Caraglia M; Vincenzi B; Luce A; Montella L; Mastella A; Mazzone S; Ricciardiello F; Carraturo M; Del Prete S; Sperlongano P
Chemotherapy; 2019; 64(1):48-56. PubMed ID: 31242489
[TBL] [Abstract][Full Text] [Related]
11. Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma.
Quan K; Xu KM; Zhang Y; Clump DA; Flickinger JC; Lalonde R; Burton SA; Heron DE
Semin Radiat Oncol; 2016 Apr; 26(2):112-9. PubMed ID: 27000507
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.
Matuschek C; Bölke E; Belka C; Ganswindt U; Henke M; Stegmaier P; Bamberg M; Welz S; Debus J; Gioules A; Voigt A; Volk G; Ohmann C; Wiegel T; Budach V; Stuschke M; Schipper J; Gerber PA; Budach W
Strahlenther Onkol; 2013 Aug; 189(8):625-31. PubMed ID: 23824104
[TBL] [Abstract][Full Text] [Related]
13. Treatment of head and neck cancers: issues for clinical pharmacists.
Scarpace SL; Brodzik FA; Mehdi S; Belgam R
Pharmacotherapy; 2009 May; 29(5):578-92. PubMed ID: 19397465
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
15. Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.
Selzer E; Liederer S; Lemaire C; Kren G; Radonjic D; Kornek G; Knocke T; Pötter R; Bachtiary B
Strahlenther Onkol; 2011 Jun; 187(6):373-7. PubMed ID: 21603990
[TBL] [Abstract][Full Text] [Related]
16. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results.
Zenda S; Onozawa Y; Tahara M; Kawashima M; Shikama N; Sasaki S; Boku N
Jpn J Clin Oncol; 2007 Oct; 37(10):725-9. PubMed ID: 17925299
[TBL] [Abstract][Full Text] [Related]
17. Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.
Roman J; Dissaux G; Gouillou M; Gobel Y; Potard G; Leclere JC; Conan-Charlet V; Gujral D; Abgral R; Guibourg B; Pradier O; Schick U
Target Oncol; 2017 Aug; 12(4):505-512. PubMed ID: 28580506
[TBL] [Abstract][Full Text] [Related]
18. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.
De Felice F; Vetrone L; Bulzonetti N; Caiazzo R; Marampon F; Musio D; Tombolini V
Med Oncol; 2019 Jun; 36(8):68. PubMed ID: 31190132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
